Evidence map›Paper›PMID 34833890›Full record

ArticleMolecules (Basel, Switzerland)2021

Design and Synthesis of (2-

Essmat M El-Sheref, Mohammed A I Elbastawesy, Alan B Brown, Ahmed M Shawky, Hesham A M Gomaa, Stefan Bräse, Bahaa G M Youssif

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Design, synthesis,RSC advances · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Design, Synthesis and Biological Evaluation ofMolecules (Basel, Switzerland) · 2022
    Article
  11. Article
  12. Synthesis of novel amidinesFrontiers in chemistry · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Essmat M El-SherefChemistry Department, Faculty of Science, Minia University, El-Minia 61519, Egypt.ORCID 0000-0002-3804-9729
Mohammed A I ElbastawesyDepartment of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Al-Azhar University, Assiut 71524, Egypt.ORCID 0000-0002-3460-0667
Alan B BrownProgram in Chemistry, Florida Institute of Technology, 150 W University Blvd, Melbourne, FL 32901, USA.
Ahmed M ShawkyScience and Technology Unit (STU), Umm Al-Qura University, Makkah 21955, Saudi Arabia.ORCID 0000-0002-3035-661X
Hesham A M GomaaPharmacology Department, College of Pharmacy, Jouf University, Sakaka 72314, Saudi Arabia.ORCID 0000-0001-7510-8428
Stefan BräseInstitute of Organic Chemistry, Karlsruhe Institute of Technology, 76131 Karlsruhe, Germany.
Bahaa G M YoussifPharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt.ORCID 0000-0002-6834-6548

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A mild and versatile method based on Cu-catalyzed [2+3] cycloaddition (Huisgen-Meldal-Sharpless reaction) was developed to tether 3,3'-((4-(prop-2-yn-1-yloxy)phenyl)methylene)

Indexed as

Antineoplastic AgentsApoptosisCell Cycle CheckpointsCell Line, TumorCell ProliferationClick ChemistryCopperDrug Screening Assays, AntitumorHumansMCF-7 CellsMolecular StructureQuinolonesStructure-Activity RelationshipTriazolesAntineoplastic AgentsCopperQuinolonesTriazolesanti-proliferativeapoptosisazidoclickquinolonestriazole

Identifiers

PMID34833890
PMCPMC8620910

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.